胡志伟,张鹏程,曾德强,张小聪

目的:观察术中腹腔灌注雷替曲塞化疗对进展期胃癌患者的疗效及安全性。方法：收集2020年2月至2021年2月在粤北人民医院胃肠外科诊断为进展期胃癌的患者84例，采用随机分组设计，试验组42例，对照组42例。试验组为手术治疗联合雷替曲塞术中腹腔灌洗化疗，对照组采用单纯手术治疗。分析两组术后血常规、肝肾功能等指标及术后感染、术后腹腔出血、肠梗阻、吻合口或残端瘘、术后住院天数等指标是否存在统计学差异。结果:试验组和对照组术后并发症的发生率无显著差异（P＞0.05），试验组和对照组术后炎症指标，肝肾功能毒性，术后主要恢复指标等均无显著差异（P＞0.05）.结论:对于进展期胃癌患者术中使用雷替曲塞腹腔灌洗化疗对患者术后血液毒性、肝肾功能等并无明显影响，不会增加术后发热、出血、感染、肠梗阻、吻合口瘘等并发症，术中使用雷替曲塞行腹腔化疗灌注措施安全可行。

雷替曲塞；腹腔灌注化疗；进展期胃癌；安全性

[1]Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015,136（5）:E359-E386.DOI:10.1002 / ijc.29210. [2]Wang L,Wu Y,Lin L,et al.Metastasis-associated in colon cancer-I upregulation predicts a poor prognosis of gastric cancer,and promotes tumor cell proliferation and invasion [J]. Int J Cancer,2013,133(6):1419-1430.[3]Cao J,Qi F,Liu T.Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis[J].Scand J Gastroenterol,2014,49(6): 690-704. [4]Coccolini F.Intraperitoneal chemotherapy in advanced gastric cancer.Meta- analysis of randomized trials.[J].European Journal of Surgical Oncology,2014,40(1):12-26. [5]左婷婷,郑荣寿,曾红梅,et al.中国胃癌流行病学现状[J].中国肿瘤临床,2017,44(01):52-8. [6]Chen XZ,Yang k,Liu J,et a1 ． Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer[J]．World J Gastroenterol,2011,17(40):4542—4544． [7]徐建军,刘殿明.雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较[J].东南国防医药,2015,17(1):38-39,60. [8] Martin S. Treatment of Pancreatic Exocrine Deficiency [J]. World Journal of Surgery, 2003,27(11):1192-1195. [9] Parkin DM, Bray F, Ferlay J, et al. GIobal cancer statistics 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108. [10] Jarmula A. Antifolate inhibitors of thymidylate synthase as anticancer drugs [J]. Mini Rev Med Chem, 2010, 10(13): 1211-1222. [11]胡俊,韦永明.雷替曲塞在晚期结直肠癌治疗中的应用价值[J].吉林医学,2011,32(34):7281.

点击下载PDF